Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q1 2024 Earnings Presentation
22 slides from Adc Therapeutics Sa's earnings presentation, May 6, 2024
Slide 1: 1Q 2024 Earnings Call
1Q 2024 Earnings Call May 6, 2024
Slide 2: Agenda
Agenda Ameet Mallik 01 Chief Executive Officer Business Update Pepe Carmona Financial Update 02 Chief Financial Officer Q&A Kristen Harrington-Smith Mohamed Zaki Chief Commercial Officer Chief Medical Officer 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 4: Key Business Updates
Key Business Updates § ZYNLONTA® 1Q 2024 net product sales of $17.8M, a 7% increase compared to 4Q 2023 Commercial Performance § Continued volume growth in the academic and community settings § LOTIS-7 cleared dose escalation; dose expansion underway with glofit combo in 2L+ DLBCL Pipeline § Initial
Slide 5: Unlocking Potential Value of Robust ADC Portfolio
Unlocking Potential Value of Robust ADC Portfolio Hematology Portfolio Solid Tumor Portfolio Short-Mid Term Mid-long Term ZYNLONTA ADCT-601 (AXL) § Maximize ZYNLONTA in 3L+ DLBCL § Optimizing dose for expansion as single agent and / or in combination in sarcoma, pancreatic, and NSCLC § Seek to expan
Slide 6: Advancing ZYNLONTA Development in B-Cell Lymphomas
Advancing ZYNLONTA Development in B-Cell Lymphomas Projected U.S. Market Value2, 2023 5-year prevalence3 DLBCL FL MZL^ Current Development Areas $3.1b2, ~109 K patients $2.6b2, ~61 K patients $1.4b2, ~38 K patients § LOTIS-5 and LOTIS-7 potential to move ZYNLONTA into 2L+ DLBCL Proportion of patient
Slide 7: ZYNLONTA R/R MZL Opportunity Overview
ZYNLONTA R/R MZL Opportunity Overview Phase 2 University of Miami IIT Initial Data Estimated 3 – 4 K 2L+ MZL patients are drug-treated in the US1; despite patients achieving durable responses, high unmet medical need remains with <30% CR for 2L+ NCCN preferred treatments2 2 FDA approved regimens (n
Slide 8: Response Rates in Relapsed / Refractory MZL for Current NCCN Preferred Regimens
Response Rates in Relapsed / Refractory MZL for Current NCCN Preferred Regimens with 2L+ Data NCCN Preferred^, FDA Approved Regimens NCCN Preferred Regimens^ CR PR CR PR 79% ORR 68% ORR 65% ORR 53% ORR 42% 36% 62% 40% 26% 29% 17% 13% 3 Zanubrutinib Zanubrutinib2 2 R2 R25 4 Benda * Obin1 Benda + + Ob
Slide 9: A Phase 2, Open-label, IIT Evaluating Loncastuximab in R/R MZL
A Phase 2, Open-label, IIT Evaluating Safety and Efficacy of Loncastuximab in R/R MZL Clinical Design Study Overview R/R MZL Previously Treated with ≥ 1 Line of Systemic § A multi-institutional study of 50 patients with r/r MZL after Therapy previous systemic treatment (clinicaltrials.gov ID: NCT052
Slide 10: Patient Baseline Characteristics from Initial Data
Patient Baseline Characteristics from Initial Data 15 evaluable patients out of 20 enrolled patients as of 04/18/2024 Baseline Characteristics N Previous Treatments N Number of patients 15 Non-systemic XRT 3 Splenectomy 1 Age, average (range), years 64 (48 – 80) Systemic Rituximab 6 Gender (M:F) 3:1
Slide 11: Initial study results from University of Miami
Initial study results from University of Miami presentation at Lymphoma Research Foundation’s 2024 MZL Scientific Workshop Data as of March 30, 2024 Initial Efficacy Findings § 13 out of 15 patients with a CR, 1 out of 15 with a PR PD Patient stopped due to a toxicity § 9 out of 13 CRs were achieved
Slide 12: LOTIS-7 Part 1 Dose Escalation
LOTIS-7 Part 1 Dose Escalation Data as of April 19, 2024 Initial Safety Findings CRS Profile § Majority of CRS events were grade 1 and no CRS > grade 2 was observed Arm E* (ZYNLONTA + Glofit) Arm F* (ZYNLONTA + Mosun) n=9 n=9 § All CRS grade 2 events responded to Tocilizumab / corticosteroids; no re
Slide 13: Developing Differentiated ADCs with a High Therapeutic Index
Developing Differentiated ADCs with a High Therapeutic Index A novel hydrophilic, highly stable, protease-cleavable linker conjugated to Exatecan NaPi2b Claudin-6 PSMA ASCT2 Target description Phosphate transporter Adhesion protein Enzymatic glycoprotein Amino acid transporter NSCLC NSCLC NSCLC Tumo
Slide 14: 1Q 2024 Selected Financial Data
1Q 2024 Selected Financial Data (in $ millions) Balance Sheet March 31, 2024 Cash and cash equivalents $234.3 GAAP Non-GAAP (Adjusted)* Statement of Operations 1Q 2024 % vs. 1Q 2023 1Q 2024 % vs. 1Q 2023 Product Revenues, Net 17.8 -5.8 17.8 -5.8 Research & Development Expenses 25.7 -32.9 26.3 -25.5
Slide 15: Completed Registered Direct Offering of $105.0M
Completed Registered Direct Offering of $105.0M § Priced a $105.0M underwritten offering, with 13,411,912 shares and 8,163,265 pre- funded warrants § Shares sold to investors at Friday closing price of $4.90 and pre-funded warrants sold at $4.81 (being the offering price per common share in the offe
Slide 16: Corporate Business Development Strategy for ADCT Portfolio
Corporate Business Development Strategy for ADCT Portfolio U.S. EX-U.S. HEMATOLOGY OVERLAND ZYNLONTA, ADCT-602 JOINT VENTURE Direct Partnership Business Development to Unlock Value SOLID TUMORS ADCT-601, Research Assets Co-development & Royalty & Co-promote* Milestones to ADCT Business Development G
Slide 17: Delivering on Our Strategy
Delivering on Our Strategy Milestones Achieved q LOTIS-7: Cleared dose escalation q r/r FL and r/r MZL IITs: Encouraging initial data shared q ADCT-601 (AXL): Dosing initiated in pancreatic q Research platform: Highlighted at Investor Event Upcoming Expected Milestones q ZYNLONTA q Achieve commercia
Slide 18: 1Q 2024 Earnings Call
Earnings Call . THERAPEUTICS Innovating Science. Inspiring Hope.
Slide 19: Reconciliation of GAAP Measures to Non-GAAP Measures
Reconciliation of GAAP Measures to Non-GAAP Measures Unaudited (in thousands, except for share and per share data) Three Months Ended March 31, (in thousands) 2024 2023 Change % Change Total operating expense $ (51,666) $ (69,202) $ 17,536 (25) % Adjustments: Share-based compensation expense (i) 158
Slide 20: Current MZL Treatment Landscape
Current MZL Treatment Landscape LoT / Epidemiology1 Treatment Paradigm2 3L+ # of treated patients T-cell-mediated therapy per year Anti-CD20-based regimens BTKis (Axi-cel) 0.8 – 1.3 K 2L # of treated patients per year Anti-CD20-based regimens BTKis 2.2 – 3.2 K 1L # of treated patients per year Anti-
Slide 21: LOTIS-7 Part 1 Dose Escalation Grade 3 and 4 Adverse Events
LOTIS 7 Part 1 Dose Escalation Grade 3 and 4 Adverse Events Regardless of relatedness, Data as of April 19, 2024 Arm E (Lonca + Glofit) Arm F (Lonca + Mosun) Total Patients Treated N=9 N=9 N=18 Patients with any grade AE 9 (100 %) 9 (100 %) 18 (100 %) Patients with Any Grade 3/4 AE 3 (33.3%) 5 (55.5
Slide 22: LOTIS-7 Part 1 Dose Escalation Summary of Serious Adverse Events
LOTIS 7 Part 1 Dose Escalation Summary of Serious Adverse Events Regardless of relatedness, Data as of April 19, 2024 Arm E (Lonca + Glofit) Arm F (Lonca + Mosun) Total Patients Treated N=9 N=9 N=18 Patients with any SAE 1 (5.5%) 5 (55.5%) 6 (33.3%) Cytokine release syndrome* 1 (5.5%) 4 (44.4%) 5 (2